Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News vTv Therapeutics begins Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes patients vTv Therapeutics has launched its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. Find out what this means for patients and investors today. byPallavi MadhirajuAugust 17, 2025